Programmatic evaluations

Mid-term evaluation of the Global Strategy to Eliminate Yellow Fever Epidemics (EYE) 2017 - 2026

The mid-term evaluation was included as a milestone in the EYE strategy and in the WHO evaluation workplan 2022–2023, and was approved by the WHO Executive Board at its 150th session in January 2022. The purpose of the evaluation was to assess the relevance, coherence, effectiveness, efficiency and sustainability of the strategy implementation to date and to review inclusion of gender, equity and human rights considerations. This included programme delivery aspects as well as strategy management and governance aspects.

Mid-term evaluation of the implementation of the Strategic Action Plan on Polio Transition (2018–2023)

The mandate to conduct a mid-term evaluation of the implementation of the Strategic Action Plan on Polio Transition (2018–2023) derives from the polio transition roadmap that was prepared to support implementation of the Strategic Action Plan. The objective of this formative evaluation was to assess the status of implementation of the Strategic Action Plan and to propose any modifications needed to adapt to the changing context. The evaluation focused on progress across the 20 polio transition priority countries and further investigated progress at the regional and global levels. It: (a) documented key achievements, best practices, challenges, gaps, and areas for improvement in the design and implementation of the Strategic Action Plan; (b) identified the key contextual factors and changes in the global public health realm that have affected the development and implementation of the Strategic Action Plan and the roadmap developed in 2018; and (c) made recommendations as appropriate on the way forward to enable the successful implementation of the plan. The Executive Summary of this evaluation report will be presented to the Seventy-fifth World Health Assembly in May 2022.

Comprehensive review of the WHO Global Action Plan on Antimicrobial Resistance (2021)

The mandate to conduct a comprehensive review of the WHO Global Action Plan on Antimicrobial Resistance derives from resolution WHA72.5 (2019). The overall purpose of this comprehensive review was to enhance current work on AMR. Based on the five primary objectives of the GAP AMR, the review documents successes, challenges and best practices, and provides lessons learned and recommendations for use by WHO and other GAP AMR stakeholders to guide future implementation of the GAP AMR and to inform decision-making on AMR.

Mid-point evaluation of the implementation of the WHO global action plan for the prevention and control of noncommunicable diseases 2013-2020 (NCD-GAP) (2020)

The mandate to conduct a mid-point evaluation of the progress achieved in the implementation of the NCD-GAP derives from paragraph 1(1) of resolution WHA66.10 (2013) which endorsed the NCD-GAP. The purpose of the evaluation was to assess the accomplishments of the six objectives of the NCD-GAP as well as the lessons learned through implementation of the NCD-GAP in Member States, by international partners and non-State actors, and at the three levels of WHO. The evaluation report documents successes, challenges and gaps in the implementation of the NCD-GAP since 2013; provides lessons learned and recommendations to improve the implementation of the NCD-GAP until 2030; and provides inputs for the next WHO global status report on noncommunicable diseases, as well as other reports, including on contributions to reducing premature mortality from NCDs by promoting mental health, reducing air pollution and strengthening health systems. The executive summary of the evaluation report was presented to the 148th session of the Executive Board in January 2021. 

EB148/7 Add.1 Executive Summary:

Final evaluation of the WHO global coordination mechanism on the prevention and control of noncommunicable diseases (2020)

The terms of reference of the GCM/NCD included a provision for both a preliminary and a final evaluation. Building on the 2017 preliminary evaluation of the GCM/NCD, the objective of the final evaluation was to assess the effectiveness of the GCM/NCD, its added value and its continued relevance to the achievement of the 2025 voluntary global targets, including its possible extension. The scope of the final evaluation involved an assessment of the results derived from the implementation of the workplan covering the period 2018–2019, which reportedly took into account the recommendations of the preliminary evaluation, as well as the workplan for 2020. It also considered the lessons learned and the extent to which the recommendations of the preliminary evaluation were actioned, and to what effect. The executive summary of the evaluation report was presented to the 148th session of the Executive Board in January 2021.

EB148/7 Add2 Executive Summary:

Evaluation of the Global strategy and action plan on ageing and health (2016-2020) (2020)

The purpose of this evaluation was to draw lessons learned from implementation of the Global strategy and action plan in order to inform the WHO Secretariat’s work on the Decade of Healthy Ageing (2020–2030). 

Evaluation of the WHO Neglected Tropical Diseases Programme (2019)

The Evaluation of the WHO Neglected Tropical Diseases Programme, with a special focus on the current neglected tropical diseases road map for implementation, documented the Programme’s successes, challenges and gaps during the period 2014-2017 and provided lessons learned and strategic recommendations for the design and operationalization of the next steps, addressing the remaining toll of neglected tropical diseases in the context of the Thirteenth General Programme of Work, 2019-2023.

Summative evaluation of the WHO Rapid Access Expansion Programme (2018)

Preliminary evaluation of the WHO global coordination mechanism on the prevention and control of noncommunicable diseases (2017)

Review of the Member State mechanism on substandard/spurious/falsely-labelled/falsified/counterfeit medical products (2017)

Comprehensive Evaluation of the Implementation of the Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property (2016)